Detection and Genotyping of Human Papilloma Virus (HPV) As a Cause of Recurrent Early Pregnancy Loss

Aya A. Hammad¹*, Neveen A. Ashaat¹, Samah F. Darwish², I.I. Moustafa³ and A.S. Amin²

¹Faculty of Women for Arts, Science and Education, Ain Shams University, Egypt
²Biotechnology Research Unit, Animal Reproduction Research, Giza, Egypt
³Department of Obstetrics & Gynecology, Faculty of Medicine, Ain Shams University, Egypt

*Corresponding author

ABSTRACT

Human papillomavirus (HPV) is the most common sexually transmitted infection (STI). HPV is so common that nearly all sexually active men and women get it at some point in their lives. The objective of this study is to assess whether or not there is an association between HPV and unexplained recurrent early pregnancy loss (REPL). Genomic DNA was extracted from the collected paired placenta and urine samples and was submitted to PCR methods with the primers MY09/11 and nPCR with the pair of primers MY09/MY11 and GP5+/6+. HPV-positive samples were typed by multiplex PCR for four high-risk HPV (HR-HPV) (HPV-16, 18, 31 and 51). Agreement between paired sample results was evaluated. The results indicated that, HPV infection was found as 16.6% and 26.7% in placental samples, 6.6% and 36.7% in urine samples by using PCR and nPCR or real-time PCR respectively. HPV-16 was the predominance HPV type in both sample (10%) followed by HPV-31 (6.6%) in both samples and HPV- types 51 and 18 (3.3%) in both samples. There was 3.3% co infection (infection by more than one type of HPV) in placenta and urine samples by types 16 and 51. There was poor agreement of placenta and urine samples results in generic and a moderate agreement for type-specific detection of HPV. The results also showed a significantly difference between number of miscarriage in HPV positive (3.38±0.744) and HPV negative (2.95±0.385) placenta samples. In conclusion HPV infection of trophoblast may cause placental dysfunction and is associated with adverse pregnancy outcomes, including recurrent early pregnancy loss.

Keywords

Human papillomavirus (HPV), Molecular diagnostics, Recurrent early pregnancy loss, Nested PCR

Article Info

Accepted: 25 December 2015
Available Online: 10 January 2016

Introduction

Human papillomavirus (HPV) is one of the commonest sexually transmitted infections. Over 50% (Up to 80%) of sexually active women are infected at some point in their lives and 10-20% develops persistent infection (Einstein et al., 2009). The study of HPV's has been driven not by these widespread in apparent infections, but by the severity to which some HPV-associated diseases can progress. Most significant of
These is cervical cancer, which can result from persistent infection with a group of “high-risk” HPVs (Goon et al., 2008 and Doorbar et al., 2012).

There was number of investigators reported that HPV infected trophoblast cells within the placenta from early pregnancy losses and it was threefold more prevalent in spontaneous abortions than in elective terminations of pregnancy (Hermonat et al., 1997; Malhomme et al., 1997 and Hermonat et al., 1998). Thus, the disruption of the trophoblastic layer by HPV could likely result in abnormal plantation or expulsion of the gestation (Clark et al., 1993).

Recurrent pregnancy loss (RPL) was defined as the occurrence of two or more failed pregnancies’, according to the American Society for Reproductive Medicine, diagnosed either by ultrasound examination or by histopathology (Allison and Schust 2009; Donckers et al., 2012 and Ibrahim et al., 2014).

There are currently several techniques for the molecular diagnosis of HPV, ranging from a conventional Polymerase Chain Reaction (PCR) methods complex, such as real-time PCR, hybrid capture (HC) and microarray (Gravitt et al., 2000 and Choi et al., 2005). The PCR technique is still considered the “gold standard” for HPV diagnosis (Trofatter, 1997).

For the genotyping of HPV, the target products amplified by PCR are subjected to sequence analysis (Asato et al., 2004), restriction fragment length polymorphism analysis (RFLP) analysis (Yoshikawa et al., 1991; Bernard et al., 1994 and Sasagawa et al., 2000), and hybridization with type-specific probes (Kleter et al., 1999; Han et al., 2006 and Jiang et al., 2006). Reverse line blot assays have also been developed and validated (Gravitt et al., 1998).

The main aim of this study was to investigate the role that could be played by HPV as a causative agent of RPL. This was based on detection of HPV in both placenta and urine samples collected from women suffering from RPL using different PCR assays including conventional, nested and qPCR assays. Additionally, comparative evaluation of the adopted PCR assays was done.

**Materials and Methods**

**Patients and Specimen Collection**

This is a case control study. Paired samples including both urine and placenta were collected. Case group included samples from women with recurrent miscarriage attending outpatient clinics of Ain Shams University Maternity Hospital, Cairo, Egypt between 24 and 38 years old (32.67 ± 3.209) and the gestational age was between 8 and 14 weeks (10.93 ± 1.982). Patients with chronic or hereditary diseases were excluded. Control group included samples collected from women presented with first missed miscarriage, with no history of recurrent early pregnancy loss and had at least one previous uneventful pregnancy with no previous obstetric history of adverse pregnancy outcomes.

All the women enrolled in the study were informed about the research objective. This study was approved by the Ethical Board of Ain Shams University, Faculty of Medicine. Each woman’s placenta and urine samples were taken on the same day; the urine specimen was self-collected on EDTA according to Antje et al., 1999 kept at-80 before DNA extraction.
DNA Extraction from Placental and Urine Samples

DNA was extracted from placenta tissue and urine samples by chelex-100 using a modified protocol from that of Walsh et al. (1991).

HPV Detection by PCR

All samples were subjected for three different PCR assays to detect HPV for comparative evaluation. A set of primer targeting the aminolevulinate delta synthase 1 gene (Gen Bank accession no. NM 000688), Table 1, was included in each PCR reaction as an internal control for DNA adequacy to avoid false-negative results in different PCR assays according to Morie et al. (2008).

Gp5+/6+conventional PCR Assay

HPV was detected by PCR using hot start master mix (QIAGEN), and the Gp5+/6+ general primers (Table 1) described by weimin et al., 1997. The PCR reaction was performed in a final volume of 25 µL containing 12.5 µl PCR Hot Start Master Mix, 25 pmol from each Gp5+/6+ primers, 0.5 µl of DNA and 6.5 µl water. The reaction condition was as follows: 40 cycles of denaturation 1 min at 95°C, annealing 1 min at 40 °C, and extension 2 min at 72°C followed by final extension cycle of 72°C for 10 min, according to De Roda husman et al., 1995.

Nested PCR Assay

In this assay, HPV detection was carried out using two rounds of PCR: the first round utilize MY09/11 primers (Gravitt et al., 2000) (Table 1), while the second round used GP5+/6+ primers, which amplify the 150 pb fragment. All reactions were performed in a final volume of 25 µL, containing hot start PCR master mix (QIAGEN). The temperature profile for the first round and for second round were performed according to Strauss et al. (1999). All PCR products were visualized on a 2.0% agarose gel.

Real Time PCR Assay

Real-time amplification of the HPV DNA was performed in a total volume of 25 µl using Gp5+/6+ primer pair. All reactions were performed in a final volume of 25 µL, containing 1× SYBR Green PCR master mix (QIAGEN), as described previously (De Araujo et al., 2009). The thermal cycle protocol was performed on one step Real-Time PCR Detection System (Corbett Research, Australia). The PCR was then followed by a melt analysis program. Melt curve analysis was performed by heating the PCR products from 60°C to 95°C. The fluorescence data was collected at the end of each extension step and continuously during the melt curve program by SYBR green channel. Each run included both positive control and negative (no template) control. Samples considered positive when its fluorescence exceed the threshold and its melt curve analysis was specific.

Genotyping of Human Papilloma Virus

HPV in positive samples were genotyped using multiplex PCR assay targeting 4 genotypes of high risk HPV using 5 sets of genotype-specific primers that could amplify specific regions of 4 types of high risk- HPV DNA (16, 18, 31, and 51). One additional primer set was used for HPV type 16 to ensure identification of its 2 serotypes (Table 1). PCR was performed with a multiplex PCR kit (Qiagen) according to Morie et al. (2008).
Statistical Analysis

Data are processed with SPSS (version 16.0). T test was used to detect difference between negative and positive HPV samples on level of patient data. Kappa agreement test was used to compare between different tests adopted for detection of HPV.

Results and Discussion

All samples including both placenta and urine samples were subjected for HPV detection by GP5+/6+ conventional PCR assay, nested PCR assay and real time PCR assay. Fig 1 and 2 showed the PCR products of both the GP5+/6+ conventional PCR assay and nested PCR assay in both placenta and urine samples, respectively. Fig 3 and 4 showed the amplification and melting curves of represented of HPV positive and negative samples using real time PCR assay in both placenta and urine samples, respectively. HPV was detected in 5 placenta samples out of 30 (16.6%) by GP5+/6+ conventional PCR assay versus 8 (26.7%) found positive by both nested and real time PCR assays. On the other hand, 2 (6.6%) urine samples were HPV positive by GP5+/6+ conventional PCR assay versus 11 (36.7%) found positive by both nested and real time PCR assays. Comparative evaluation between the three tests adopted for detection of HPV detection revealed a substantial agreement (Kappa agreement = 62.3%) between GP5+/6+ conventional PCR and the nested or real time PCR assay in placenta samples , while a fair agreement (kappa agreement = 22.6%) was detected between the same assays in urine samples . Complete agreement (kappa agreement= 100%) was detected between the nested and the real time PCR assays as they both detected the same number of positive HPV samples.

Additionally, a multiplex PCR assay specific for genotypes 16, 18, 31, 51 of HPV were used to detect the specific genotype in all the HPV positive samples (Fig. 5). Table 2 showed the number of different genotypes detected in different types of samples. Comparison between HPV positive and negative samples on the level of patient data was statistically evaluated. Significant difference was found between number of miscarriage in HPV positive (3.38±0.744) and HPV negative (2.95±0.385) placenta samples. Also, significant difference was found in gestational age between HPV positive (12.09±1.7) and HPV negative (10.26±1.851) urine samples (Table 3).

HPVs are well known to be pathogenic viruses and are the largest risk factor in the development of cervical cancer (Melbye and Frisch, 1998). Trophoblasts may represent a new host cell type; these data also support the hypothesis that HPV infection of trophoblasts may be linked to some spontaneous abortions (Noventa et al., 2014). The search for factors that may be implicated in spontaneous abortion has led to the examination of numerous factors, including maternal age, number of miscarriage and gestational age. There are several comparative studies of different methods for HPV-DNA detection. DNA detection in urine implies a number of challenges: it is a diluted sample and contains both known, such as urea and nitrites, and unknown polymerase chain reaction (PCR) inhibitors (Khan et al., 1991). Antje et al. (1999) showed that human DNA containing 40 mM EDTA stored at room temperature for 8 days was less degraded than the DNA in urine samples without EDTA frozen at -20ºC. EDTA , known to be an effective nuclease inhibitor, is a chelating agent of bi-valent cations cofactors of DNA nucleases (Baker, 2009).
### Table 1: Primers used in Different PCR Assays

<table>
<thead>
<tr>
<th>PCR assay</th>
<th>Primer Name</th>
<th>Primer sequence (5’-3’)</th>
<th>Product size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gp5+/6+ set</td>
<td>Gp5+/6+ F</td>
<td>TTT GTT ACT GTG GTA GAT ACT AC GAA AAA TAA ACT GTA AAT CATATT</td>
<td>150 bp</td>
</tr>
<tr>
<td></td>
<td>Gp5+/6+ R</td>
<td>(Weimin et al., 1997)</td>
<td></td>
</tr>
<tr>
<td>MY09/11 set</td>
<td>MY09/11 F</td>
<td>CGT CCM ARR GGA WAC TGA TC GCM CAG GGW CAT AAY AAT GG</td>
<td>450 bp</td>
</tr>
<tr>
<td></td>
<td>MY9/11 R</td>
<td>(Gravitt et al., 2000)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PPx16L/F</td>
<td>CGC ACA AAA CGT GCTCGGCT ACC TGG GAG GCC TTG TTCCCAATG GA</td>
<td>217 bp</td>
</tr>
<tr>
<td></td>
<td>PPx16L/R</td>
<td>(Morie et al., 2008)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PPx16U/F</td>
<td>TCC TGC AGG TAC CAA TGGGGA AGA GG TGC CAT ACC CGC TGT CTTCGC TTT</td>
<td>397 bp</td>
</tr>
<tr>
<td></td>
<td>PPx16U/R</td>
<td>(Morie et al., 2008)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PP x18/F</td>
<td>AAC AGT CCA TTA GGG GAG CGG CTG GA TGC CGC CAT GTT CGC CATTTG</td>
<td>187 bp</td>
</tr>
<tr>
<td></td>
<td>PP x18/R</td>
<td>(Morie et al., 2008)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PP x31/F</td>
<td>GCG GTC CAA ACG CTC TACAAA ACG CAC T GCA GGG GCA CCA ACA TCA ACA ATT CCA</td>
<td>360 bp</td>
</tr>
<tr>
<td></td>
<td>PP x31/R</td>
<td>(Morie et al., 2008)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PP x51/F</td>
<td>CAA CTA GCA ACG GCG ATG GAC TG CTG CTT CGC GGG CTG ACT AGA A</td>
<td>299 bp</td>
</tr>
<tr>
<td></td>
<td>PP x51/R</td>
<td>(Morie et al., 2008)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IC/F</td>
<td>TTA TCC CGA GTC CCC CAGGCC TTT CT TGG CTT GGC CCC AAC TTCCAT CA</td>
<td>99 bp</td>
</tr>
<tr>
<td></td>
<td>IC/R</td>
<td>(Morie et al., 2008)</td>
<td></td>
</tr>
</tbody>
</table>

The degenerate base code is as follows: M = A or C, W = A or T, Y = C or T, and R = A or G). F: forward primer; R: reverse primer; IC: internal control.

### Table 2: Different HPV Genotypes Detected in HPV Positive Placenta and Urine Samples

<table>
<thead>
<tr>
<th>HPV Genotypes</th>
<th>Placenta No.=8</th>
<th>Urine No.=11</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPV-16</td>
<td>3 (10%)</td>
<td>3 (10%)</td>
</tr>
<tr>
<td>HPV-18</td>
<td>1 (3.3%)</td>
<td>1 (3.3%)</td>
</tr>
<tr>
<td>HPV-31</td>
<td>2 (6.6%)</td>
<td>2 (6.6%)</td>
</tr>
<tr>
<td>HPV-51</td>
<td>1 (3.3%)</td>
<td>1 (3.3%)</td>
</tr>
<tr>
<td>HPV-16+51</td>
<td>1 (3.3%)</td>
<td>1 (3.3%)</td>
</tr>
<tr>
<td>Untyped</td>
<td>0</td>
<td>3 (10%)</td>
</tr>
</tbody>
</table>
### Table 3: Comparison Between HPV Positive and Negative Samples on the Level of Patient Number of Miscarriage, Patient Age (Year) and Gestational Age (week)

<table>
<thead>
<tr>
<th>Patient data</th>
<th>Placenta samples</th>
<th>Urine samples</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>+ve HPV No. =8</td>
<td>-ve HPV No. =22</td>
</tr>
<tr>
<td>No. of Miscarriage Mean±SD</td>
<td>3.38±0.744*</td>
<td>2.95±0.385</td>
</tr>
<tr>
<td>Age Mean±SD</td>
<td>33.9±1.356</td>
<td>32.23±3.59</td>
</tr>
<tr>
<td>Gestational Age Mean±SD</td>
<td>11.75±1.982</td>
<td>10.64±1.94</td>
</tr>
</tbody>
</table>

* =P<0.05 Significant

### Fig. 1: Agarose Gel Electrophoresis of PCR Products of Placenta and Urine Samples obtained by amplification using Gp5+/6+ Conventional PCR
(a) Representatives of Placenta Samples; M: 100 bp molecular DNA marker; PC: Positive Control; lanes 3, 6, 7, 10 and 11: positive samples. Lanes 1, 2, 5, 6, 9, 10 and 13-23: negative samples. NC: negative control
(b) Representatives of urine samples; lane M: 100 bp molecular DNA marker; PC: positive control, lanes 3 and 6: positive samples, Lanes: 1, 2, 4, 5 and 7-23: negative samples. NC: negative control
Fig. 2 Agarose gel electrophoresis of PCR products of placenta and urine samples obtained by amplification using nested PCR (a) Representatives of placenta samples; M: 100 bp molecular DNA marker; PC: positive control, lanes 3, 6, 7, 10, 11, 12, 17 and 21: positive samples. Lanes 1, 2, 4, 5, 8, 9, 13, 14, 15, 16, 18-20, 22 and 23: negative samples. NC: negative control (b) Representatives of urine samples; lane M: 100 bp molecular DNA marker; PC: positive control. Lanes 3, 4, 6, 9, 12, 14, 15, 17, 19, 21 and 23: positive samples. Lanes 1, 2, 5, 7, 8, 10, 11, 13, 16, 18, 20 and 22: negative samples. NC: negative control.
Fig. 3 Amplification plot and melting curve for HPV detection by Gp5+/6+ SYBR Green Q-RT PCR in placenta samples. (a) Amplification plot for detection of HPV in placenta samples using real time PCR assay: Relative fluorescence units are plotted against cycle number (Ct). (b) Melting curve of HPV positive and negative samples. The x-axis indicates the melting temperatures while the y-axis indicates the fluorescence intensity. : (θ) HPV positive samples, Tm73.95 C ;(#) HPV negative samples.

Fig. 4 Amplification plot and melting curve for HPV detection by Gp5+/6+ SYBR Green Q-RT PCR in urine samples. (a) Amplification plot for detection of HPV in placenta samples using real time PCR assay: Relative fluorescence units are plotted against cycle number (Ct). (b) Melting curve of HPV positive and negative samples. The x-axis indicates the melting temperatures while the y-axis indicates the fluorescence intensity. : (θ) HPV positive samples, Tm73.95 C ;(#) HPV negative samples.
In the present study, the HPV-DNA analysis by PCR GP5+/6+ was observed in (16.6%) of placenta samples and (6.6%) in urine samples, whereas nPCR technique found HPV positivity in (26.7%) in placenta samples and (36.7%) in urine samples (Fig. 1 and 2). The results indicated that, the use of primers pair MY09/11 and GP5+/6+ in a nPCR assay increases the sensitivity of HPV detection compared with PCR assay and this may be associated with the HPV genome copy number was too low to be detected after a single round PCR and this was agreement with Coser et al. (2011). The results of 128 clinical samples submitted to simple PCR and nested-PCR for detection of HPV, 67.5% were increased in detection rate compared with single PCR. On the other hand, Ludmila et al. (2013) studied infection of HPV in 251 cervical samples by PCR and nPCR methods. The HPV-DNA analysis was observed in 17 samples and in more 75 samples, respectively, increasing up to 4 times the detection of viral DNA. According to Demathe et al. (2010), the variations of HPV-DNA detection suggest a potential difference in the ability to amplify fragments of different sizes and specific HPV types, in accordance with the methods of DNA detection used, and also the types of material (smears, frozen material, paraffin or formalin embedded) and the design of primers used.

In our present study, the HPV-DNA analysis by SYBR Green qualitative real-time (Q-T) PCR was observed in (26.7%) of placenta sample and (36.7%) in urine sample, and from this data, there was 100% perfect agreement between placenta and urine samples tested by nested PCR and SYBR Green Q-RT PCR. we concluded that SYBR Green Q-RT PCR is a sensitive and easy-to-perform technique for HPV screening and this was in agreement with De Araujo et al. (2009).

Type-specific viral identification revealed that HPV-16 had the greatest prevalence in both samples (n=3, 10%), followed by type 31 (n= 2, 6.6%); types 51 and 18 (n=1, 3.3%) in both placenta and urine samples.
(Fig. 5), there was 3 urine samples not typed and that may be another HR-HPV or low – HPV. Our data was in agreement with Shaltout et al. (2014) who studied four hundred and forty-three from cervical samples women; HPV DNA was detected in 10.4% of women; a single HPV-type infection was found in 6.5% and multiple infections in 3.8%. The most prevalent HR types among HPV-positive women were HPV-16 (19.6%) and HPV-31 and HPV-51 (15.2% each). The prevalence of HPV-18 was low (6.5%). Some investigators reported an active viral genome expression (both early and late genes) in trophoblastic cells previously when cultured with HPV 16,18,11,31, it were shown to undergo complete life cycles in a trophoblastic cells and they decreases trophoblast cell number and cell adhesion which could result in abnormal placentation and maybe in early pregnancy loss (Liu et al., 2001 and You et al., 2003). These effects were also confirmed by Gomez et al. (2008) who found a 3- to 6-fold greater rate of apoptosis in trophoblastic cells transfected with a plasmid containing the entire HPV-16 genome and a progressive decrease of trophoblast invasion ability from day 3 until 15 after transfection. The reasons which could explain the reduction of invasiveness of trophoblastic cells were suggested by Boulenouar et al. (2010) who found a down-regulation of E- in trophoblastic cells expressing HPV-16 viral genome.

In conclusion, women with recurrent miscarriage have a higher prevalence of HPV+DNA tests than controls. The nested and real time-PCR assays are more sensitive than conventional PCR assay for detection of HPV in placental and urine samples.

References


Immun. 29, 199–205.


than 18 years in Egypt: a multicenter, observational study. International Journal of Infectious Diseases. (29); 226–231.

SPSS 2007. Statistical Package for Social Sciences, SPSS Inc, Chicago, IL, USA Copyright© for Windows, version 160 SPSS.


How to cite this article:

http://dx.doi.org/10.20546/ijcmas.2016.501.069